Author:
Martis Lena-Sophie,Højgaard Kristoffer,Holmes Megan C.,Elfving Betina,Wiborg Ove
Abstract
AbstractDepression-associated cognitive impairments are among the most prevalent and persistent symptoms during remission from a depressive episode and a major risk factor for relapse. Consequently, development of antidepressant drugs, which also alleviate cognitive impairments, is vital. One such potential antidepressant is vortioxetine that has been postulated to exhibit both antidepressant and pro-cognitive effects. Hence, we tested vortioxetine for combined antidepressant and pro-cognitive effects in male Long-Evans rats exposed to the chronic mild stress (CMS) paradigm. This well-established CMS paradigm evokes cognitive deficits in addition to anhedonia, a core symptom of depression. Learning and memory performance was assessed in the translational touchscreen version of the paired-associates learning task. To identify the mechanistic underpinning of the neurobehavioural results, transcriptional profiling of genes involved in the stress response, neuronal plasticity and genes of broad relevance in neuropsychiatric pathologies were assessed. Vortioxetine substantially relieved the anhedonic-like state in the CMS rats and promoted acquisition of the cognitive test independent of hedonic phenotype, potentially due to an altered cognitive strategy. Minor alterations in gene expression profiling in prefrontal cortex and hippocampus were found. In summary, our findings suggest that vortioxetine exhibits an antidepressant effect as well as behavioural changes in a translational learning task.
Publisher
Springer Science and Business Media LLC
Reference67 articles.
1. World Health Organisation. Depression-Fact sheet. World Health Organisation (2020). Available at: https://www.who.int/en/news-room/fact-sheets/detail/depression. (Accessed 26 April 2020).
2. Warden, D., Rush, J., Trivedi, M. H., Fava, M. & Wisniewski, S. R. The STAR*D project results: a comprehensive review of findings. Curr. Psychiatry Rep. 9, 449–459 (2007).
3. Conradi, H. J., Ormel, J. & de Jonge, P. Presence of individual (residual) symptoms during depressive episodes and periods of remission: a 3-year prospective study. Psychol. Med. 41, 1165–1174 (2011).
4. Darcet, F., Gardier, A. M., Gaillard, R., David, D. J. & Guilloux, J. P. Cognitive dysfunction in major depressive disorder. A translational review in animal models of the disease. Pharmaceuticals 9, 9 (2016).
5. Reppermund, S., Ising, M., Lucae, S. & Zihl, J. Cognitive impairment in unipolar depression is persistent and non-specific: further evidence for the final common pathway disorder hypothesis. Psychol. Med. 39, 603–614 (2009).
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献